Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 16/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.43 |
| ▸ | PLG | P00747 | 3/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | F7 | P08709 | 2/20 | 0.42 |
| ▸ | PROC | P04070 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075571 | 0.92 | F10 (0.49) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7074088 | 0.91 | F10 (0.45) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7070281 | 0.91 | F10 (0.43) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7074957 | 0.90 | F10 (0.45) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7088543 | 0.90 | SCN9A (0.45) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7072101 | 0.90 | F10 (0.46) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7072626 | 0.89 | F10 (0.44) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7096906 | 0.89 | F10 (0.46) | SCN9AF10PRSS1F2 | |
| SCHEMBL7072789 | 0.89 | SCN9A (0.49) | SCN9AF10PRSS1F2PRSS2 | |
| SCHEMBL7072039 | 0.89 | F10 (0.46) | SCN9AF10PRSS1F2PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | MERCK-PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | F12, F11, PLAT | SCN9A 3149/4885F10 17/4885PRSS1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.